STAT+: Drugmakers promise to stockpile certain drugs as part of new drug pricing deals
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
WASHINGTON \u2014 Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump administration focused on lowering U.S. drug prices to levels available to other wealthy countries.<\/p>\n
The administration announced Friday that nine more drugmakers agreed to so-called most favored nation prices, bringing the total number of companies to sign such deals this year to 14. The agreements are similar to those shared earlier this year: brand drugmakers will lower prices and boost domestic manufacturing in return for avoiding tariffs.<\/p>\n
But the stockpile is a new aspect. Some of the nine companies agreed to donate six months\u2019 worth of certain drug ingredients to the Strategic Active Pharmaceutical Ingredient Reserve and to make finished-dose products from those ingredients during emergencies. Among them, Merck will supply the bulk ingredients for its antibiotic ertapenem; Bristol Myers Squibb will provide the blood thinner apixaban, commonly sold under the brand name Eliquis; and GSK will donate albuterol.<\/p>\n
Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n